TCA
VRTX icon

Trifecta Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Trifecta Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.32M Sell
16,745
-12
-0.1% -$5.32K 1.07% 29
2026
Q1 		$7.48M Buy
16,757
+260
+2% +$121K 1.16% 29
2025
Q4 		$7.48M Buy
16,497
+664
+4% +$286K 1.11% 28
2025
Q3 		$6.2M Buy
15,833
+493
+3% +$206K 0.94% 36
2025
Q2 		$6.83M Buy
15,340
+802
+6% +$370K 1.14% 34
2025
Q1 		$7.05M Buy
14,538
+573
+4% +$267K 1.48% 20
2024
Q4 		$5.62M Buy
13,965
+430
+3% +$199K 1.11% 29
2024
Q3 		$6.29M Buy
13,535
+219
+2% +$105K 1.32% 22
2024
Q2 		$6.24M Buy
13,316
+955
+8% +$415K 1.38% 17
2024
Q1 		$5.17M Buy
12,361
+526
+4% +$222K 1.26% 23
2023
Q4 		$4.82M Buy
11,835
+350
+3% +$129K 1.33% 22
2023
Q3 		$3.99M Buy
11,485
+685
+6% +$240K 1.28% 22
2023
Q2 		$3.8M Buy
10,800
+990
+10% +$334K 1.22% 22
2023
Q1 		$3.09M Buy
9,810
+5,260
+116% +$1.58M 1.09% 26
2022
Q4 		$1.31M Buy
+4,550
New +$1.39M 0.52% 51

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Trifecta Capital Advisors's VRTX Position: Q2 2026 in Review

Trifecta Capital Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 0.07% in Q2 2026, selling an estimated $5.32K and leaving 16,745 shares worth $8.32M. The position accounts for 1.07% of the portfolio, ranked #29.

Trifecta Capital Advisors first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Trifecta Capital Advisors held 16,745 shares of Vertex Pharmaceuticals worth $8.32M as of Q2 2026.
  • Trifecta Capital Advisors sold 12 Vertex Pharmaceuticals shares in Q2 2026, an estimated $5.32K.
  • Vertex Pharmaceuticals made up 1.07% of Trifecta Capital Advisors's portfolio in Q2 2026, its #29 holding.
  • Trifecta Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.